Associate Director, Medical Affairs Belgium

Alexion is AstraZeneca’s Rare Disease unit, focused on developing and delivering therapies for conditions with high unmet need, particularly those involving complement system dysregulation and select metabolic/hematologic disorders. The portfolio includes Soliris (eculizumab) and Ultomiris (ravulizumab), alongside an expanding pipeline across indications such as PNH, aHUS, generalized myasthenia gravis (gMG), and NMOSD. Alexion integrates R&D, Medical, and Commercial capabilities to advance rare disease science, accelerate patient access, and uphold rigorous standards of compliance, evidence generation, and patient-centricity. 

Position Summary

The Medical Affairs role anchors Alexion’s scientific leadership and evidence generation, ensuring patient‑centric, compliant, and data‑driven medical strategy across the product lifecycle—from launch planning to post‑marketing optimization—in collaboration with cross‑functional R&D, Regulatory, Commercial, Market Access, Q...